These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 26689274

  • 1. HYPERREFLECTIVE RETINAL SPOTS AND VISUAL FUNCTION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN CENTER-INVOLVING DIABETIC MACULAR EDEMA.
    Vujosevic S, Berton M, Bini S, Casciano M, Cavarzeran F, Midena E.
    Retina; 2016 Jul; 36(7):1298-308. PubMed ID: 26689274
    [Abstract] [Full Text] [Related]

  • 2. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L, Cserhati S, Seidensticker F, Liegl R, Kampik A, Ulbig M, Neubauer AS, Kernt M.
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [Abstract] [Full Text] [Related]

  • 3. RETINAL LAYER RESPONSE TO RANIBIZUMAB DURING TREATMENT OF DIABETIC MACULAR EDEMA: Thinner is Not Always Better.
    Ebneter A, Wolf S, Abhishek J, Zinkernagel MS.
    Retina; 2016 Jul; 36(7):1314-23. PubMed ID: 26735563
    [Abstract] [Full Text] [Related]

  • 4. CORRELATION OF OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI WITH VISUAL OUTCOMES IN DIFFERENT PATTERNS OF DIABETIC MACULAR EDEMA.
    Kang JW, Chung H, Chan Kim H.
    Retina; 2016 Sep; 36(9):1630-9. PubMed ID: 26900741
    [Abstract] [Full Text] [Related]

  • 5. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
    Santos AR, Alves D, Santos T, Figueira J, Silva R, Cunha-Vaz JG.
    Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of inner and outer retinal thickness in patients receiving intravitreal ranibizumab injections for diabetic macular edema.
    Dursun A, Ozec AV, Kirboga K, Dursun FG, Toker MI, Erdogan H, Arici MK.
    Eur J Ophthalmol; 2016 Jan; 26(1):48-53. PubMed ID: 26220809
    [Abstract] [Full Text] [Related]

  • 7. The area of fixation covaries with short-term changes in visual acuity after anti-vascular endothelial growth factor treatment in patients with diabetic macular oedema.
    Jakobsen NS, Larsen DA, Bek T.
    Acta Ophthalmol; 2018 Nov; 96(7):744-748. PubMed ID: 29687595
    [Abstract] [Full Text] [Related]

  • 8. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
    Vujosevic S, Torresin T, Bini S, Convento E, Pilotto E, Parrozzani R, Midena E.
    Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
    [Abstract] [Full Text] [Related]

  • 9. OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.
    Santos AR, Costa MÂ, Schwartz C, Alves D, Figueira J, Silva R, Cunha-Vaz JG.
    Retina; 2018 Jun; 38(6):1110-1119. PubMed ID: 28613220
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
    Kaya M, Karahan E, Ozturk T, Kocak N, Kaynak S.
    Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
    [Abstract] [Full Text] [Related]

  • 11. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
    Ou WC, Brown DM, Payne JF, Wykoff CC.
    Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
    [Abstract] [Full Text] [Related]

  • 12. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A.
    Retina; 2006 Aug; 26(9):999-1005. PubMed ID: 17151486
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.
    Laugesen CS, Ostri C, Brynskov T, Lund-Andersen H, Larsen M, Vorum H, Sørensen TL.
    Acta Ophthalmol; 2017 Feb; 95(1):28-32. PubMed ID: 27473397
    [Abstract] [Full Text] [Related]

  • 14. Diabetic Macular Edema With and Without Subfoveal Neuroretinal Detachment: Two Different Morphologic and Functional Entities.
    Vujosevic S, Torresin T, Berton M, Bini S, Convento E, Midena E.
    Am J Ophthalmol; 2017 Sep; 181():149-155. PubMed ID: 28687219
    [Abstract] [Full Text] [Related]

  • 15. PREDICTIVE VALUE OF OPTICAL COHERENCE TOMOGRAPHIC FEATURES IN THE BEVACIZUMAB AND RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA (BRDME) STUDY.
    Fickweiler W, Schauwvlieghe AME, Schlingemann RO, Maria Hooymans JM, Los LI, Verbraak FD, BRDME Research Group.
    Retina; 2018 Apr; 38(4):812-819. PubMed ID: 28406860
    [Abstract] [Full Text] [Related]

  • 16. Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting.
    Maggio E, Sartore M, Attanasio M, Maraone G, Guerriero M, Polito A, Pertile G.
    Am J Ophthalmol; 2018 Nov; 195():209-222. PubMed ID: 30098350
    [Abstract] [Full Text] [Related]

  • 17. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab.
    Baget-Bernaldiz M, Romero-Aroca P, Bautista-Perez A, Mercado J.
    Doc Ophthalmol; 2017 Oct; 135(2):85-96. PubMed ID: 28779336
    [Abstract] [Full Text] [Related]

  • 18. Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.
    Okamoto M, Yamashita M, Ogata N.
    Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):885-892. PubMed ID: 29492689
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.